 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12...191192193194195196197198199200201...203204» |
- | Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
New P4 trial, FDG PET: TARGET: Treatments Against RA and Effect on FDG-PET/CT (clinicaltrials.gov) - Feb 27, 2015
P4, N=200, Not yet recruiting, Sponsor: Brigham and Women's Hospital
- |||| remtolumab (ABT-122) / AbbVie
Enrollment open, P2 data: A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX) (clinicaltrials.gov) - Feb 27, 2015
P2, N=220, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Trial primary completion date: Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice (clinicaltrials.gov) - Feb 27, 2015
P=N/A, N=300, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Mar 2017
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Visual II: Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis (clinicaltrials.gov) - Feb 24, 2015
P3, N=250, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Mar 2017 Recruiting --> Active, not recruiting
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion, PK/PD data: Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Feb 24, 2015
P2, N=31, Completed, Sponsor: AbbVie
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: REACH: Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA (clinicaltrials.gov) - Feb 24, 2015
P=N/A, N=1013, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| etrolizumab (RG7413) / Roche
Trial initiation date: HIBISCUS I: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Feb 24, 2015
P3, N=350, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Initiation date: Feb 2015 --> Nov 2014
- || Humira (adalimumab) / Eisai, AbbVie
Observational data, Trial primary completion date: SPACTIVE: Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium (clinicaltrials.gov) - Feb 20, 2015
P=N/A, N=200, Recruiting, Sponsor: AbbVie
Initiation date: Feb 2015 --> Nov 2014 Trial primary completion date: Dec 2016 --> Jun 2017
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation) (clinicaltrials.gov) - Feb 20, 2015
P=N/A, N=100, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Mar 2015 --> Sep 2015
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date, HEOR: Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life (clinicaltrials.gov) - Feb 20, 2015
P=N/A, N=200, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Mar 2015 --> Sep 2015 Trial primary completion date: Jan 2015 --> Apr 2015
- ||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed, Enrollment change, Trial primary completion date: Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab (clinicaltrials.gov) - Feb 20, 2015
P4, N=64, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Jan 2015 --> Apr 2015 Recruiting --> Active, not recruiting | N=100 --> 64 | Trial primary completion date: Nov 2016 --> May 2015
- |||||| etrolizumab (RG7413) / Roche
Enrollment open, Trial initiation date: HIBISCUS I: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Feb 20, 2015
P3, N=350, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=100 --> 64 | Trial primary completion date: Nov 2016 --> May 2015 Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> Feb 2015
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=1000, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> Feb 2015 N=550 --> 1000
- Enrollment open, Trial primary completion date: ULSPABIT: Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting Biological Therapy (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=100, Recruiting, Sponsor: Diakonhjemmet Hospital
N=550 --> 1000 Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2013 --> Nov 2016
- | Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment change, Trial termination: RA-COMPARE: An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate (clinicaltrials.gov) - Feb 19, 2015
P3, N=452, Terminated, Sponsor: Sanofi
N=700 --> 452 | Recruiting --> Terminated; Due to small number of participants entering randomization. Not a safety issue.
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: P @ Work: Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 12, 2015
P=N/A, N=760, Recruiting, Sponsor: AbbVie
- |||| Tremfya (guselkumab) / J&J
Trial completion: X-PLORE: A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Feb 9, 2015
P2, N=293, Completed, Sponsor: Janssen Inc.
Not a safety issue. Active, not recruiting --> Completed
- Humira (adalimumab) / Eisai, AbbVie
Trial initiation date: Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis (clinicaltrials.gov) - Feb 6, 2015
P=N/A, N=30, Not yet recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed Initiation date: Jul 2014 --> Feb 2015
- |||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment open, Monotherapy: Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH) (clinicaltrials.gov) - Feb 6, 2015
P3, N=340, Recruiting, Sponsor: Sanofi
Initiation date: Jul 2014 --> Feb 2015 Not yet recruiting --> Recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Trial initiation date, Trial primary completion date: ORIENT: Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=100, Not yet recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Initiation date: Dec 2014 --> Mar 2015 | Trial primary completion date: Dec 2018 --> Mar 2019
- Humira (adalimumab) / Eisai, AbbVie
Phase classification: Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Feb 5, 2015
P1/2, N=8, Terminated, Sponsor: Wayne State University
Initiation date: Dec 2014 --> Mar 2015 | Trial primary completion date: Dec 2018 --> Mar 2019 Phase classification: P2 --> P1/2
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: ANTIBODY-RA: Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab (clinicaltrials.gov) - Feb 3, 2015
P4, N=629, Completed, Sponsor: Pfizer
Phase classification: P2 --> P1/2 Recruiting --> Completed
- ||||| Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma
New P4 trial: MAZERATI: Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept (clinicaltrials.gov) - Feb 3, 2015
P4, N=90, Not yet recruiting, Sponsor: University of Pittsburgh
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: PIONEER (OLE): Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Feb 2, 2015
P3, N=540, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Trial primary completion date: Jan 2015 --> Jul 2015
- |||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment open: RA-COMPARE: An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate (clinicaltrials.gov) - Feb 2, 2015
P3, N=700, Recruiting, Sponsor: Sanofi
Trial primary completion date: Jan 2015 --> Jul 2015 Active, not recruiting --> Recruiting
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: VISUAL III: A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis (clinicaltrials.gov) - Jan 30, 2015
P3, N=400, Enrolling by invitation, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Recruiting Trial primary completion date: Mar 2016 --> Mar 2017
- ||| remtolumab (ABT-122) / AbbVie
P2 data, Trial initiation date: A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Jan 30, 2015
P2, N=160, Recruiting, Sponsor: AbbVie
Trial primary completion date: Mar 2016 --> Mar 2017 Initiation date: Jun 2014 --> Jan 2014
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: IMAgINE 2: Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806 (clinicaltrials.gov) - Jan 28, 2015
P3, N=100, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Initiation date: Jun 2014 --> Jan 2014 Trial primary completion date: Nov 2014 --> Sep 2016
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Trial primary completion date: Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=203, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Nov 2014 --> Sep 2016 N=266 --> 203 | Trial primary completion date: Sep 2015 --> Mar 2016
- ||||| remtolumab (ABT-122) / AbbVie
New P2 trial, P2 data: A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX) (clinicaltrials.gov) - Jan 28, 2015
P2, N=220, Not yet recruiting, Sponsor: AbbVie
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Trial primary completion date: RADAR: A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis (clinicaltrials.gov) - Jan 28, 2015
P4, N=320, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
N=266 --> 203 | Trial primary completion date: Sep 2015 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2021 --> Jul 2015
- |||| Olumiant (baricitinib) / Incyte, Eli Lilly
Trial primary completion date: RA-BEAM: A Study in Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jan 22, 2015
P3, N=1280, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2021 --> Jul 2015 Trial primary completion date: Dec 2014 --> Mar 2015
- Trial primary completion date: Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity (clinicaltrials.gov) - Jan 13, 2015
P=N/A, N=398, Recruiting, Sponsor: University Hospital, Montpellier
Trial primary completion date: Dec 2014 --> Mar 2015 Trial primary completion date: May 2014 --> Jun 2016
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: AS PMOS: Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients (clinicaltrials.gov) - Jan 7, 2015
P=N/A, N=200, Recruiting, Sponsor: AbbVie
- |||||||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
New P3 trial, Monotherapy: Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH) (clinicaltrials.gov) - Jan 7, 2015
P3, N=340, Not yet recruiting, Sponsor: Sanofi
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / AbbVie
New P3 trial: Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease (clinicaltrials.gov) - Jan 6, 2015
P3, N=100, Recruiting, Sponsor: Tokyo Medical and Dental University
- Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
HEOR: Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation (clinicaltrials.gov) - Jan 2, 2015
P=N/A, N=40, Recruiting, Sponsor: University Hospital Case Medical Center
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change: Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study), a Follow-up Survey of Study P12-069 (clinicaltrials.gov) - Dec 24, 2014
P=N/A, N=172, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: May 2014 --> Jun 2016 Active, not recruiting --> Completed | N=125 --> 172
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate (clinicaltrials.gov) - Dec 24, 2014
P3, N=114, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed | N=125 --> 172 Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: ORIENT: Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA (clinicaltrials.gov) - Dec 23, 2014
P=N/A, N=100, Not yet recruiting, Sponsor: AbbVie
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical: Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice (clinicaltrials.gov) - Dec 22, 2014
P=N/A, N=1035, Completed, Sponsor: Regionshospitalet Viborg, Skive
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Trial initiation date: SUSI-CS: Stavanger IBD Study - Cross Sectional (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=200, Recruiting, Sponsor: Helse Stavanger HF
Active, not recruiting --> Completed Initiation date: Apr 2014 --> Dec 2014
- |||||| Tremfya (guselkumab) / J&J
Enrollment open: VOYAGE 1: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (clinicaltrials.gov) - Dec 17, 2014
P3, N=750, Recruiting, Sponsor: Janssen Research & Development, LLC
Initiation date: Apr 2014 --> Dec 2014 Not yet recruiting --> Recruiting
- || clazakizumab (CSL300) / CSL Behring
P2b data, Trial primary completion date: Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate (clinicaltrials.gov) - Dec 9, 2014
P2b, N=406, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2013 --> Sep 2012
- Humira (adalimumab) / Eisai, AbbVie
Trial termination: The Effect of Adalimumab on the Bone Microstructure in Crohn's Disease (CD) Patients (clinicaltrials.gov) - Dec 6, 2014
P2, N=34, Terminated, Sponsor: Gerhard Rogler
Trial primary completion date: Dec 2013 --> Sep 2012 Recruiting --> Terminated; not enough patients enrolled
- ||| Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Trial primary completion date: ORBIT: Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy (clinicaltrials.gov) - Dec 6, 2014
P4, N=302, Active, not recruiting, Sponsor: University of Glasgow
Recruiting --> Terminated; not enough patients enrolled Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Dec 2014
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: ADA-IFX: Switching From Adalimumab to Infliximab (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=40, Recruiting, Sponsor: University Hospital, Ghent
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Dec 2014 Trial primary completion date: Jul 2013 --> Jul 2015
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Trial completion, Trial primary completion date, IO biomarker: Regulatory T-cells in Psoriasis Patients as Targets for Therapy (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=38, Completed, Sponsor: University of Aberdeen
Trial primary completion date: Jul 2013 --> Jul 2015 Recruiting --> Completed | Trial primary completion date: Aug 2011 --> Sep 2013
- | Enbrel (etanercept) / Pfizer, Amgen
Phase classification: ANTIBODY-RA: Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab (clinicaltrials.gov) - Nov 28, 2014
P4, N=600, Recruiting, Sponsor: Pfizer
Recruiting --> Completed | Trial primary completion date: Aug 2011 --> Sep 2013 Phase classification: P=N/A --> P4
- | Xeljanz (tofacitinib) / Pfizer
Clinical: ORAL STRATEGY: An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate (clinicaltrials.gov) - Nov 20, 2014
P4, N=1080, Recruiting, Sponsor: Pfizer
Phase classification: P=N/A --> P4 Phase classification: P3 --> P4